Table 1.
Summary of relationship between VEGF isoform expression and pathologic features in colorectal and non-small cell lung cancers (p < 0.05 was considered significant)
| Pathologic features | VEGF isoform (kDa) | |||
| VEGF 23 kDa | p valuea | VEGF 26 kDa | p valuea | |
| Colorectal cancer (total 76 cases) | 42 (55.3%) | 53 (69.7%) | ||
| Gender | ||||
| Female (46 cases) | 28 (60.8%) | 0.224 | 32 (69.5%) | 0.968 |
| Male (30 cases) | 14 (46.7%) | 21 (70.0%) | ||
| Tumour size | ||||
| ≤ 5 cm (45 cases) | 30 (66.7%)b | < 0.05 | 30 (66.7%) | 0.483 |
| > 5 cm (31 cases) | 12 (38.7%) | 23 (74.1%) | ||
| Histological differentiation | ||||
| Well (42 cases) | 22 (52.4%) | 0.574 | 28 (66.7%) | 0.517 |
| Moderate or Poor (34 cases) | 20 (58.8%) | 25 (73.5%) | ||
| Tumour stage grouping | ||||
| Early stage (I or II) (34 cases) | 23 (67.6%) | 0.09 | 19 (55.9%) | < 0.01 |
| Late stage (III or IV) (42 cases) | 19 (45.2%) | 34 (80.9%) | ||
| Metastasis | ||||
| No (49 cases) | 31 (63.3%) | 0.059 | 29 (59.2%) | < 0.01 |
| Yes (27 cases) | 11 (40.7%) | 24 (88.9%) | ||
| Lung cancer (total 18 cases) | 16 (88.9%) | 16 (88.9%) | ||
| Gender | ||||
| Female (10 cases) | 8 (80.0%) | 0.477 | 8 (80.0%) | 0.477 |
| Male (8 cases) | 8 (100.0%) | 8(100%) | ||
| Tumour size | ||||
| ≤ 5 cm (7 cases) | 7 (100.0%) | 0.231 | 7 (100.0%) | 0.231 |
| > 5 cm (11 cases) | 9 (81.8%) | 9 (81.8%) | ||
| Histological differentiation | ||||
| Well (5 cases) | 4 (80.0%) | 0.490 | 4 (80.0%) | 0.490 |
| Moderate or Poor (13 cases) | 12 (92.3%) | 12 (93.3%) | ||
| Tumour stage grouping | ||||
| Early stage (I or II) (2 cases) | 1 (50.0%) | 0.210 | 0 (0.0%) | < 0.01 |
| Late stage (III or IV) (16 cases) | 15 (93.8%) | 16 (100%) | ||
| Metastasis | ||||
| No (7 cases) | 6 (85.7%) | 1.00 | 5 (71.4%) | 0.137 |
| Yes (11 cases) | 10 (90.9%) | 11 (100.9%) | ||
a chi-square test, b percentage in relation to total number of cases in each pathological features